Judah Frommer
Stock Analyst at Morgan Stanley
(0.63)
# 4,254
Out of 5,099 analysts
507
Total ratings
45.3%
Success rate
-2.1%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Reiterated: Hold | $42 → $57 | $55.52 | +2.67% | 7 | Oct 30, 2026 | |
| KYMR Kymera Therapeutics | Rated: Buy | $135 → $150 | $127.09 | +18.03% | 13 | Oct 30, 2026 | |
| BCAX Bicara Therapeutics | Reiterated: Buy | $37 → $41 | $8.96 | +357.59% | 20 | Oct 20, 2026 | |
| CLDX Celldex Therapeutics | Rated: Buy | $57 | $29.71 | +91.85% | 14 | Oct 20, 2026 | |
| IMMX Immix Biopharma | Rated: Buy | $19 → $20 | $7.71 | +159.40% | 3 | Oct 20, 2026 | |
| AGMB AgomAb Therapeutics NV | Rated: Buy | $28 | $6.85 | +308.76% | 15 | Oct 19, 2026 | |
| LKFT Lakefront Biotherapeutics NV | Rated: Hold | $26 | $32.15 | -19.13% | 59 | Oct 5, 2026 | |
| ABVX ABIVAX Société Anonyme | Reiterated: Buy | $180 | $88.71 | +102.91% | 9 | Sep 28, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Hold | n/a | $11.95 | - | 15 | Sep 28, 2026 | |
| ATTO Attovia Therapeutics | Rated: Buy | $39 | $15.27 | +155.40% | 2 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $34 | $8.76 | +288.13% | 1 | Aug 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $7.63 | +135.91% | 22 | Aug 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $201 → $206 | $152.17 | +35.37% | 3 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 → $32 | $28.38 | +12.76% | 12 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $53 → $57 | $26.81 | +112.61% | 3 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $1.62 | - | 10 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $2.05 | +582.93% | 4 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $1.07 | +180.37% | 15 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $26 | $5.94 | +337.71% | 9 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 → $23 | $13.86 | +65.95% | 7 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $34 → $38 | $32.00 | +18.75% | 7 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $18 | $8.59 | +109.55% | 6 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $93 → $104 | $68.12 | +52.67% | 27 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $104 → $119 | $117.59 | +1.20% | 14 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $141 → $139 | $18.54 | n/a | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $138 | $0.0002 | n/a | 9 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $4.02 | n/a | 8 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $0.48 | n/a | 8 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $26.99 | n/a | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $22 | $19.90 | n/a | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $7 | $8.82 | n/a | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $13 | $0.2344 | n/a | 4 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $8 | $3.74 | n/a | 9 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 → $55 | $23.87 | n/a | 6 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 → $46 | $104.44 | n/a | 3 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 → $24 | $101.36 | n/a | 7 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 → $26 | $52.49 | n/a | 10 | Jul 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $13.27 | n/a | 2 | Jul 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $90 → $95 | $88.98 | n/a | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $328 | $1,019.26 | n/a | 6 | Jul 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $35 | $66.81 | n/a | 28 | Jun 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $125 → $116 | $236.19 | n/a | 9 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €22.00 → €24.00 | €32.16 | n/a | 3 | Jun 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $98 → $107 | $134.07 | n/a | 19 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $154 → $178 | $130.52 | n/a | 10 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $38 | $109.46 | n/a | 4 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $67 → $63 | $74.11 | n/a | 17 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $96.51 | n/a | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $17.42 | n/a | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $35.96 | n/a | 1 | Mar 6, 2019 |
Genmab
Oct 30, 2026
Reiterated: Hold
Price Target: $42 → $57
Current: $55.52
Upside: +2.67%
Kymera Therapeutics
Oct 30, 2026
Rated: Buy
Price Target: $135 → $150
Current: $127.09
Upside: +18.03%
Bicara Therapeutics
Oct 20, 2026
Reiterated: Buy
Price Target: $37 → $41
Current: $8.96
Upside: +357.59%
Celldex Therapeutics
Oct 20, 2026
Rated: Buy
Price Target: $57
Current: $29.71
Upside: +91.85%
Immix Biopharma
Oct 20, 2026
Rated: Buy
Price Target: $19 → $20
Current: $7.71
Upside: +159.40%
AgomAb Therapeutics NV
Oct 19, 2026
Rated: Buy
Price Target: $28
Current: $6.85
Upside: +308.76%
Lakefront Biotherapeutics NV
Oct 5, 2026
Rated: Hold
Price Target: $26
Current: $32.15
Upside: -19.13%
ABIVAX Société Anonyme
Sep 28, 2026
Reiterated: Buy
Price Target: $180
Current: $88.71
Upside: +102.91%
4D Molecular Therapeutics
Sep 28, 2026
Reiterated: Hold
Price Target: n/a
Current: $11.95
Upside: -
Attovia Therapeutics
Sep 3, 2026
Rated: Buy
Price Target: $39
Current: $15.27
Upside: +155.40%
Aug 24, 2026
Initiated Coverage: Buy
Price Target: $34
Current: $8.76
Upside: +288.13%
Aug 24, 2026
Reiterated: Buy
Price Target: $18
Current: $7.63
Upside: +135.91%
Aug 17, 2026
Reiterated: Buy
Price Target: $201 → $206
Current: $152.17
Upside: +35.37%
Aug 17, 2026
Reiterated: Hold
Price Target: $22 → $32
Current: $28.38
Upside: +12.76%
Aug 13, 2026
Rated: Buy
Price Target: $53 → $57
Current: $26.81
Upside: +112.61%
Aug 12, 2026
Reiterated: Sell
Price Target: n/a
Current: $1.62
Upside: -
Aug 12, 2026
Rated: Buy
Price Target: $14
Current: $2.05
Upside: +582.93%
Aug 11, 2026
Reiterated: Hold
Price Target: $3
Current: $1.07
Upside: +180.37%
Aug 10, 2026
Rated: Buy
Price Target: $26
Current: $5.94
Upside: +337.71%
Aug 10, 2026
Rated: Buy
Price Target: $20 → $23
Current: $13.86
Upside: +65.95%
Aug 6, 2026
Rated: Buy
Price Target: $34 → $38
Current: $32.00
Upside: +18.75%
Aug 6, 2026
Reiterated: Buy
Price Target: $17 → $18
Current: $8.59
Upside: +109.55%
Jul 31, 2026
Reiterated: Buy
Price Target: $93 → $104
Current: $68.12
Upside: +52.67%
Jul 29, 2026
Reiterated: Hold
Price Target: $104 → $119
Current: $117.59
Upside: +1.20%
Aug 3, 2023
Reiterated: Hold
Price Target: $141 → $139
Current: $18.54
Upside: n/a
Jun 5, 2023
Reiterated: Buy
Price Target: $138
Current: $0.0002
Upside: n/a
May 16, 2023
Reiterated: Buy
Price Target: $13
Current: $4.02
Upside: n/a
May 15, 2023
Reiterated: Buy
Price Target: $40
Current: $0.48
Upside: n/a
May 5, 2023
Reiterated: Buy
Price Target: $28
Current: $26.99
Upside: n/a
Apr 3, 2023
Reiterated: Buy
Price Target: $21 → $22
Current: $19.90
Upside: n/a
Mar 31, 2023
Reiterated: Buy
Price Target: $8 → $7
Current: $8.82
Upside: n/a
Mar 28, 2023
Reiterated: Buy
Price Target: $16 → $13
Current: $0.2344
Upside: n/a
Mar 9, 2023
Downgraded: Hold
Price Target: $11 → $8
Current: $3.74
Upside: n/a
Feb 28, 2023
Reiterated: Buy
Price Target: $51 → $55
Current: $23.87
Upside: n/a
Feb 24, 2023
Reiterated: Buy
Price Target: $57 → $46
Current: $104.44
Upside: n/a
Aug 4, 2020
Reiterated: Buy
Price Target: $23 → $24
Current: $101.36
Upside: n/a
Jul 30, 2020
Reiterated: Hold
Price Target: $22 → $26
Current: $52.49
Upside: n/a
Jul 27, 2020
Reiterated: Buy
Price Target: $18
Current: $13.27
Upside: n/a
Jul 22, 2020
Rated: Hold
Price Target: $90 → $95
Current: $88.98
Upside: n/a
Jul 8, 2020
Reiterated: Hold
Price Target: $328
Current: $1,019.26
Upside: n/a
Jun 18, 2020
Reiterated: Hold
Price Target: $35
Current: $66.81
Upside: n/a
Jun 10, 2020
Rated: Buy
Price Target: $125 → $116
Current: $236.19
Upside: n/a
Jun 3, 2020
Reiterated: Hold
Price Target: €22.00 → €24.00
Current: €32.16
Upside: n/a
May 28, 2020
Rated: Buy
Price Target: $98 → $107
Current: $134.07
Upside: n/a
May 22, 2020
Reiterated: Hold
Price Target: $154 → $178
Current: $130.52
Upside: n/a
May 21, 2020
Rated: Buy
Price Target: $31 → $38
Current: $109.46
Upside: n/a
May 5, 2020
Rated: Buy
Price Target: $67 → $63
Current: $74.11
Upside: n/a
May 4, 2020
Reiterated: Buy
Price Target: $39
Current: $96.51
Upside: n/a
Mar 6, 2020
Downgraded: Hold
Price Target: n/a
Current: $17.42
Upside: n/a
Mar 6, 2019
Initiated Coverage: Hold
Price Target: n/a
Current: $35.96
Upside: n/a